Wim K. Bleeker

TL;DR: IgG4 Fab arm exchange is suggested to be an important biological mechanism that provides the basis for the anti-inflammatory activity attributed to IgG4 antibodies.

TL;DR: The results show the versatility of daratumumab to effectively kill CD38-expressing tumor cells, including patient MM cells, via diverse cytotoxic mechanisms, and support clinical development of darsatumab for the treatment of CD 38-positive MM tumors.

TL;DR: Investigation of whether plasma concentrations of antibody corresponding to relatively modest neutralization titers in vitro could protect macaques from repeated intravaginal exposure to low doses of a simian immunodeficiency virus–HIV chimera that uses the CC chemokine receptor 5 (CCR5) co-receptor suggests lower amounts of antibody than previously considered protective may provide benefit in the context of typical human exposure to HIV-1.

TL;DR: It is demonstrated that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.

TL;DR: It is shown that natalizumab exchanges Fab arms with endogenous human IgG4 in natalIZumab-treated individuals, and mutations that completely prevent Fab-arm exchange in vivo should be considered when designing therapeutic IgG 4 antibodies.